Eidos Therapeutics (Eidos Therapeutics) Debt-to-Equity : 0.18 (As of Sep. 2020)

View and export this data going back to 2018. Start your Free Trial

What is Eidos Therapeutics Debt-to-Equity?

Eidos Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2020 was $0.60 Mil. Eidos Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2020 was $20.87 Mil. Eidos Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2020 was $122.86 Mil. Eidos Therapeutics's debt to equity for the quarter that ended in Sep. 2020 was 0.17.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Eidos Therapeutics's Debt-to-Equity or its related term are showing as below:

EIDX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.12 Max: 0.18
Current: 0.18

During the past 4 years, the highest Debt-to-Equity Ratio of Eidos Therapeutics was 0.18. The lowest was 0.01. And the median was 0.12.

EIDX's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.145 vs EIDX: 0.18

Eidos Therapeutics Debt-to-Equity Historical Data

The historical data trend for Eidos Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eidos Therapeutics Debt-to-Equity Chart

Eidos Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Debt-to-Equity

0.12

Eidos Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Debt-to-Equity	Get a 7-Day Free Trial											0.03	0.12	0.12	0.14	0.18

Competitive Comparison of Eidos Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Eidos Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eidos Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eidos Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Eidos Therapeutics's Debt-to-Equity falls into.

Eidos Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Eidos Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2019 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.554	+	20.703)	/	171.427
	=	0.12

Eidos Therapeutics's Debt to Equity Ratio for the quarter that ended in Sep. 2020 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.599	+	20.868)	/	122.856
	=	0.17

Eidos Therapeutics (NAS:EIDX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Eidos Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Eidos Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Eidos Therapeutics (Eidos Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eidos Therapeutics Inc (NAS:EIDX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

101 Montgomery Street, Suite 2000, San Francisco, CA, USA, 94104

Website

https://www.eidostx.com

Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, including the transport of essential hormones and vitamins. The company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR.

Executives

Uma Sinha	director, officer: Chief Scientific Officer	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101
Franco Valle	officer: Senior Vice President, Finance	999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Cameron Turtle	officer: Chief Business Officer	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94104
Jonathan C Fox	officer: See Remarks	C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Suzanne Sawochka Hooper	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Douglas Rohlen	director	3600 HOLLY LANE NORTH, SUITE 40 PLYMOUTH MN 55447
Eric Aguiar	director	888 7TH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Rajeev M. Shah	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ali J. Satvat	director, 10 percent owner	C/O KOHLBERG KRAVIS ROBERTS & CO., 2800 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
William Lis	director	PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Christine Siu	officer: CFO and Secretary	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101
Bridgebio Pharma, Inc.	10 percent owner	421 KIPLING STREET PALO ALTO CA 94301
Neil Kumar	director, 10 percent owner, officer: Chief Executive Officer	C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Hoyoung Huh	director	C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Peter Kolchinsky	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116